Navigation Links
Debiopharm Group to Support Ascepion in the Development of Debio 1144 for the Treatment of Chinese Cancer Patients

LAUSANNE, Switzerland and SUZHOU, China, April 18, 2013 /PRNewswire/ --

Suzhou Ascepion Pharmaceuticals, Inc. (Ascepion), a Chinese leading biotech company focusing on the discovery and development of world-class molecular targeted innovative drugs and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies, announced today that Debiopharm will support further development in China of Debio 1144, a small molecule in preclinical development for the treatment of a large spectrum of solid tumors.

Debiopharm and Ascepion had previously signed a license agreement for the development and commercialization of Debio 1144, an orally available multikinase inhibitor. After having generated positive preclinical results with the product, Debiopharm has decided to support Ascepion for further development of Debio 1144 in China as it is well designed for the treatment of certain types of cancers that are highly represented in China. 

"This is an opportunity for Ascepion to develop an anti-cancer agent tailored to the Chinese market," said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™. "At Debiopharm we value sharing our competences with a Chinese company in view of developing a product with a potential to treat various cancers highly prevalent in emerging markets."

"The disease spectrum of the Chinese population suggests the product will be well suited for its market. Thus it holds a great promise for certain cancer types in Chinese patients," commented Dr. Shan Jiang , President and CEO of Ascepion Pharmaceuticals.

About Debio 1144

Debio 1144 is a multikinase inhibitor, which has demonstrated strong efficacy in several preclinical models. It is orally available and has a large therapeutic index.

About Suzhou Ascepion Pharmaceuticals Inc.

Based in Suzhou, China, Suzhou Ascepion Pharmaceuticals, Inc. is a leading biopharmaceutical company in China dedicated to the discovery and development of breakthrough small molecule drugs. Suzhou Ascepion Pharmaceuticals possesses a fully integrated platform and proprietary technologies for the discovery and development of small molecule therapeutics targeting signal transduction pathways in a systematic and productive manner. The company has developed a pipeline of innovative small molecule drugs for the treatment of oncology and related diseases. For additional information on Suzhou Ascepion Pharmaceuticals, please visit

About Debiopharm Group™

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalized medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information about Debiopharm Group™, please visit:

Debiopharm S.A. Contact    
Mrs Beatrice Hirt
Communication Coordinator
Tel.: +41(0)21-321-01-11
Fax: +41(0)21-321-01-69
Additional Media Contacts
In London
Brian Hudspith
Tel: +44(0)20-7379-5151

In New York
Russo Partners, LLC
Martina Schwarzkopf , Ph.D.
Account Executive
Tel: +1-212-845-4292
Fax: +1-212-845-4260

Ascepion Contact
Ms. Min Wang
Corporate administration
Tel.: +86-512-62956001
Fax: +86-512-62956001-8004

SOURCE The Debiopharm Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
2. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
3. The Japanese Cancer Association and Debiopharm Group Present Doctors Oshima and Tanaka with the 2012 JCA-Mauvernay Award for their Innovative and Outstanding Cancer Research
4. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
5. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
6. Watson to Acquire Actavis Group for EUR4.25 Billion
7. CentraState and Freehold Radiology Group train physicians from China
8. Winner Medical Group Inc. to Host Second Quarter 2012 Earning Conference Call on Thursday, May 10, 2012 at 9:00 p.m. EDT
9. Okuma America Chooses The Daniel Group To Provide Customer Service Research
10. H. D. Smith Signs Three Year Prime Vendor Agreement with PharmacyGPO Buying Group
11. PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor
Post Your Comments:
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... 2016  VMS Rehab Systems, Inc. ( ) ... measures required to build a strong and stable market ... listed on the OTC Markets-pink current trading platform. ... "We are seeing an anomaly in market trading activities ... by the Company, but shareholders and market players as ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... District , the only authorized OSHA Training Institute Education Center headquartered in Northern ... protecting their workers from extreme heat at their worksites. Employers with workers ...
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced today its affiliation with Tennessee Counseling Association. This new relationship ... of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
Breaking Medicine News(10 mins):